The Company’s lead candidate, EDG-5506, an investigational orally administered small molecule designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, is advancing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results